iSBTc 22nd Annual Meeting

November 2 - 4, 2007
Seaport World Trade Center
Boston, Massachusetts

Saturday Presentations
Slides for select presentations below have been provided by the corresponding speaker for your convenience.
Please click the Click to view presentation next to the speaker's name for the slides you wish to view.

Schedule at a Glance  |  Presentations  |  Friday Presentations  |  Saturday Presentations  |  Sunday Presentations

Saturday, November 3
8:00 am - 8:45 am Saturday Keynote Address
Adoptive T Cell Therapy: Grand Challenges and Opportunities
Click to view presentationCarl H. June, MD - University of Pennsylvania
8:45 am - 11:30 am Plenary Session: Immuoregulation and Mediated Tolerance
Vincenzo Bronte, MD - Istituto Oncologico Veneto
F. Stephen Hodi, MD - Dana-Farber Cancer Institute
8:45 am - 9:00 am Elevated Foxp3+CD4+CD25+ Regulatory T Cells in Tumor-Bearing Mice Suppress T-Cell Priming, Effector-Cell Function and Anti-Tumor Immunity
Zuqiang Liu, PhD - University of Pittsburgh School of Medicine
9:00 am - 9:30 am Manipulating Immune Tolerance Unmasks the Latent Immune-Modulating Potential of Cancer Therapeutics
Leisha A. Emens, MD, PhD - Johns Hopkins University
9:30 am - 9:45 am Different Flavors of Regulatory T-Cell (Treg) Subsets in
Patients with Cancer and Their Role in Tumor Escape

Click to view presentationChristoph Bergmann, MD, PhD - University of Duisburg-Essen
9:45 am - 10:00 am Ex Vivo Depletion of CD81+ Tumor-Induced Regulatory T Cells Restores Priming of Tumor-Specific Effector T Cells Generated in Reconstituted, Lymphopenic Hosts
Christian Poehlein, MD - Earle A. Chiles Research Institute
10:00 am - 10:15 am Foxp3 is Expressed by Tumor Cells, Virally Transformed B Cells, and Germ Cells
Click to view presentationWeisan Chen, PhD - Ludwig Institute for Cancer Research
10:45 am - 11:00 am TGF-Beta Signaling Plays a Crucial Role for De Novo Induction of
Adaptive Regulatory T Cells but Is Not Required for the
Immunosuppressive Effect Mediated by Tumor-Induced Regulatory T Cells

Ulf Petrausch, MD - Earle A. Chiles Research Institute
11:00 am - 11:30 am Myeloid-Derived Suppressor Cells in Cancer
Vincenzo Bronte, MD - Istituto Oncologico Veneto
1:30 pm - 3:00 pm Concurrent Session I: Tumor Recognition / Immune Evasion
Paul F. Robbins, PhD - National Cancer Institute
Thomas Spies, PhD - Fred Hutchinson Cancer Research Center
1:30 pm - 2:00 pm Adoptive Immunotherapy of Malignancies with Gene Modified, EBV-Specific, Cytotoxic T-Cell Lines
Click to view presentationMalcolm K. Brenner, MD, PhD - Baylor College of Medicine
2:00 pm - 2:30 pm Therapeutically Accessible Molecules That Regulate the Regulators
Click to view presentationDrew M. Pardoll, MD, PhD - Johns Hopkins University School of Medicine
2:30 pm - 2:45 pm Tumor-Derived Macrophage Migration Inhibitory Factor (MIF)
Inhibits Immune Reactivity to Neuroblastoma In Vivo

Click to view presentationBryon D. Johnson, PhD - Medical College of Wisconsin
2:45 pm - 3:00 pm 5-aza-2’- Deoxycytidine Treatment Increases Expression of Tumor
Associated Antigens in Human Melanoma

Click to view presentationTimothy Haggerty, PhD - CytoCure LLC
1:30 pm - 3:00 pm Concurrent Session II: New Agents
Elizabeth A. Repasky, PhD - Rosewell Park Cancer Institute
Brian I. Rini, MD - Cleveland Clinic Taussig Cancer Center
1:30 pm - 1:45 pm PTTG-1: An Immunological Target for Multiple Myeloma
Maurizio Chiriva, PhD - Texas Tech University Health Sciences Center
1:45 pm - 2:00 pm A Phase II Study of Tremelimumab (CP-675,206), an Anti-CTLA4
Monoclonal Antibody, in Patients with Refractory Metastatic Colorectoal Cancer

Click to view presentationKi Y. Chung, MD - Memorial Sloan-Kettering Cancer Center
2:00 pm - 2:15 pm Immune-Related Adverse Events in Patients with Melanoma Treated with Tremelimumab (CP-675,206)
Dimitri Pavlov, PhD - Pfizer, Inc.
2:15 pm - 2:30 pm EGFRVIII Vaccine (CDX-110) Alone and with Simultaneous
Temozolomide in Patients with Newly Diagnosed, Resected, EGFRVIII Positive GBM

Click to view presentationJohn Sampson, MD, PhD - Duke University Medical Center
2:30 pm - 3:00 pm Novel Agents in Renal Cell Carcinoma: Challenges and
Opportunities in Capitalizing on Active Therapy

Click to view presentationBrian I. Rini, MD - Cleveland Clinic Taussig Cancer Center
3:20 pm - 4:45 pm iSBTc Presidential Session
Chair: Jon M. Wigginton, MD - Merck & Co., Inc.
3:20 pm - 3:25 pm Introduction
Jon M. Wigginton, MD - Merck & Co., Inc.
3:25 pm - 3:45 pm Apoptosis of Circulating Tumor-Antigen Specific TH1 CD4+ T Cells from Melanoma Patients
Amy K. Wesa, PhD - University of Pittsburgh School of Medicine
3:45 pm - 4:05 pm Priming and Selection of Allorestricted, Peptide-Specific T Cells for Adoptive Therapy of Tumors
Susanne Wilde - Institute of Molecular Immunology
4:05 pm - 4:25 pm Retrospective Analysis of Interleukin-2 Therapy in Patients with Metastatic Renal Cell Carcinoma Who had Received Prior Antiangiogenic Therapy
Click to view presentationTalya Schwarzberg, MD - Beth Israel Deaconess Medical Center
4:25 pm - 4:45 pm CD4+CD25highFoxp3+ T Regulatory Cells Kill Autologous CD8(+) and
CD4(+) T Cells Using GranzymeB and Fas/FasL-Mediated Pathways

Click to view presentationLaura Strauss, PhD - San Raffaele Telethon Institute for Gene Therapy

Creative Commons License
All presentations are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.